Telotristat: all 24 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine TumorActive, not recruitingNCT04810091Phase 3Results posted
- Telotristat With Lutathera in Neuroendocrine TumorsTerminatedNCT04543955Phase 2Results posted
- Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic CancerCompletedNCT03910387Phase 2Results posted
- A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract CancerTerminatedNCT03790111Phase 2Results posted
- AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine NeoplasmCompletedNCT03453489Phase 2Results posted
- Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal FunctionCompletedNCT03442725Phase 1Results posted
- Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy SubjectsCompletedNCT02683577Phase 1Results posted
- Telotristat Etiprate for Carcinoid Syndrome TherapyCompletedNCT02063659Phase 3Results posted
- Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome SymptomsCompletedNCT02026063Phase 3Results posted
- TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)CompletedNCT01677910Phase 3Results posted
- A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative ColitisCompletedNCT01456052Phase 2Results posted
- Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid SyndromeCompletedNCT01104415Phase 2Results posted
- Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide TherapyCompletedNCT00853047Phase 2Results posted
- Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid SyndromeWithdrawnNCT04776876Phase 2
- Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat EthylWithdrawnNCT04713202Phase 2
- Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine TumorsWithdrawnNCT04672876Phase 2
- Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid SyndromeWithdrawnNCT04065165Phase 3
- Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic ImpairmentCompletedNCT03423446Phase 1
- A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy SubjectsCompletedNCT03302845Phase 1
- Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy SubjectsCompletedNCT02195635Phase 1
- An Open-Label Food Effect Study of Telotristat EtiprateCompletedNCT02157584Phase 1
- An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy SubjectsCompletedNCT02157558Phase 1
- A Thorough QT Study of Telotristat EtiprateCompletedNCT02155205Phase 1
- A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy SubjectsCompletedNCT02147808Phase 1